L
Luis Brandao
Researcher at University of Colorado Denver
Publications - 9
Citations - 332
Luis Brandao is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Leukemia & Receptor tyrosine kinase. The author has an hindex of 9, co-authored 9 publications receiving 300 citations. Previous affiliations of Luis Brandao include Anschutz Medical Campus.
Papers
More filters
Journal ArticleDOI
Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia.
Rachel M. A. Linger,Alisa B. Lee-Sherick,Deborah DeRyckere,Rebecca A. Cohen,Kristen M. Jacobsen,Amy McGranahan,Luis Brandao,Amanda Winges,Kelly K. Sawczyn,Xiayuan Liang,Amy K. Keating,Aik Choon Tan,H. Shelton Earp,Douglas K. Graham +13 more
TL;DR: Ectopic expression of the Mer receptor tyrosine kinase is reported in pre-B-cell ALL cell lines and pediatric patient samples and it is suggested that inhibitors of Mer may potentiate lymphoblast killing when used in combination with chemotherapy.
Journal ArticleDOI
Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress.
Adil Anwar,Amy K. Keating,David Joung,Susan Sather,Grace K. Kim,Kelly K. Sawczyn,Luis Brandao,Peter M. Henson,Douglas K. Graham +8 more
TL;DR: The ability of Mer RTK to promote macrophage survival in disease states that involve an oxidative stress environment is demonstrated and the first report of Mer activation in response to oxidative stress is reported.
Journal ArticleDOI
Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia
Luis Brandao,A Winges,Sandra Christoph,Susan Sather,Justine Migdall-Wilson,Jennifer Schlegel,Amy McGranahan,Dexiang Gao,Xiayuan Liang,Deborah DeRyckere,Douglas K. Graham +10 more
TL;DR: Results suggest that inhibition of MerTK is a promising therapeutic strategy for the treatment of leukemia and may allow for dose reduction of currently used chemotherapeutics resulting in decreased rates of therapy-associated toxicities.
Journal ArticleDOI
Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.
Rachel M. A. Linger,Deborah DeRyckere,Luis Brandao,Kelly K. Sawczyn,Kristen M. Jacobsen,Xiayuan Liang,Amy K. Keating,Douglas K. Graham +7 more
TL;DR: Ectopic expression of the receptor tyrosine kinase Mer is reported in pediatric B-cell ALL and it is suggested that inhibitors of Mer will interact synergistically with currently used therapies, allowing for dose reduction resulting in decreased toxicity and increased survival rates.
Journal ArticleDOI
Prolonged Exposure to a Mer Ligand in Leukemia: Gas6 Favors Expression of a Partial Mer Glycoform and Reveals a Novel Role for Mer in the Nucleus
Justine Migdall-Wilson,Christine Bates,Jennifer Schlegel,Luis Brandao,Rachel M. A. Linger,Deborah DeRyckere,Douglas K. Graham +6 more
TL;DR: This study explores Mer behavior following prolonged exposure to Gas6, a context similar to the Gas6-enriched microenvironment of the bone marrow, where a steady supply of ligand facilitates continuous engagement of Mer and likely sustains the presence of leukemic cells.